• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training


Sales targets: Challenging but achievable !

Posted by pharmintel on October 10, 2019

Category: Blog
Target setting is mostly a negotiation process across sales managers; often subjective with little data involved. However, adjustments to individual territory targets are not allowed and there are no clear rules and no clear ownership of the target setting process. Target setting process is too time-consuming process and deadlines are missed frequently. Sales target are not well managed and create perception of mid way game changing. Target setting process is a black box. Sales representatives
Well, it is a very complex process. If you are not sure about the particular KPI’s which should be considered for sales forecasting then your sales will surely go in negative direction. In this article we will discuss about the proper methodology which an analyst can use to forecast drug sales. Basically you need to be clear on the type of forecasting required for your project. Is it patient based forecasting? If so what geographies

Artificial Intelligence and Intelligent Augmentation

Posted by pharmintel on October 6, 2019

Category: Blog
Artificial Intelligence (AI) and Intelligent Augmentation (IA) in pharmaceutical industry present with a real opportunity to do R&D differently. There needs to be a fundamental shift in drug discovery and AI and IA both holds the key to bringing revolution to the pharma industry into the 21st Century. The current drug discovery process needs to shift dramatically in order to meet the needs both of society and patients. AI and IA both can operate more

CART Cell Therapy in Solid Tumors: Pipeline update Sep2019

Posted by pharmintel on September 29, 2019

Category: Blog
CAR T cell therapy has been a success in hematological malignancies. The FDA and EMA approved CART19 (Kymriah & Yescarta) to treat pediatric relapsed or refractory acute lymphoblastic leukemia (ALL) and for adult relapsed or refractory large B cell lymphoma in 2017 & 2018 respectively. For solid tumors, CAR T cell therapy has shown promising results in early phase of clinical trials. Results of most of the trials are awaited. Here is the glimpse for
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Unmet Medical Need (UMN) Parameters Current Unmet Medical Need in ATTR-CM Unmet Medical Need after Vyndaqel and Vyndamax Treatment Adequacy Current treatment provides symptomatic relief. New treatment affects disease progression Disease Severity Cardiac involvement
+91 9643310025, 9643312749
© 2019 Pharmintel